Triple-negative breast cancer (TNBC) is typically treated with chemotherapeutic agents, including
carboplatin (Cb), an
DNA platinating agent. The O6-methylguanine-DNA-methyltransferase gene (MGMT) encodes for the
protein O6-alkylguanine-DNA-alkyltransferase (MGMT
protein). MGMT
protein is involved in DNA repair mechanisms to remove mutagenic and cytotoxic adducts from O6-guanine in
DNA. In
glioblastoma multiforme, MGMT methylation status is a predictive
biomarker for increased response to
temozolomide therapy. It has been suggested, that MGMT
protein may have relevance for cellular adaptation and could have an influence on resistance to
carboplatin therapy. We investigated the influence of MGMT promoter methylation on
pathologic complete response and survival of patients with TNBC treated in the neoadjuvant GeparSixto trial. In 174 of 210 available TNBC
tumors a valid MGMT promoter methylation status was determined by pyrosequencing of 5 CpG islands. In 21.8%, we detected a mean MGMT promoter methylation >10%. Overall, MGMT promoter methylation was not significantly associated with pathological complete response (pCR) rate. After stratification for the two
therapy arms with and without Cb no statistically significant differences in
therapy response rates between the two MGMT promoter methylation groups could be observed. Our results show that different MGMT promoter methylation status is not related to different
chemotherapy response rates in the TNBC setting in GeparSixto.